Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intrathecal Administration of MELPIDA (AAV9/AP4M1) For Hereditary Spastic Paraplegia Type 50 (SPG50): A Phase 3, Open-Label Trial With Matched Prospective Concurrent Control Arm

NCT06692712 is registered in ClinicalTrials.gov with Elpida Therapeutics SPC as lead sponsor.

NCT NCT06692712
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06692712 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intrathecal Administration of MELPIDA (AAV9/AP4M1) For Hereditary Spastic Paraplegia Type 50 (SPG50): A Phase 3, Open-Label Trial With Matched Prospective Concurrent Control Arm
Lead sponsor
Elpida Therapeutics SPC
Phase
Phase 3
Overall status
Recruiting
Start date
April 1, 2026
Completion date
June 1, 2032
Enrollment
24 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hereditary spastic paraplegia type 50